+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hand-foot syndrome (palmar-plantar erythrodysesthesia



Hand-foot syndrome (palmar-plantar erythrodysesthesia



Schweizerische Medizinische Wochenschrift 130(40): 1413-1416



The hand-foot syndrome (HFS) is an erythematous skin lesion of the palma and planta of the hand and feet is most often caused by cytostatic chemotherapy. The impact on the patients' quality of life depends on the extent of the disease. The pathogenesis of the hand-foot syndrome has not yet been sufficiently clarified and it can only be treated symptomatically. We performed an extensive literature search in Medline to evaluate the current state of knowledge concerning the hand-foot syndrome and conclude with practical advice to physicians treating patients with hand-foot syndrome.

(PDF emailed within 1 workday: $29.90)

Accession: 046211117

Download citation: RISBibTeXText

PMID: 11059033


Related references

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5): 257-271, 2010

Antineoplastic TherapyInduced Palmar Plantar Erythrodysesthesia (Hand-Foot) Syndrome. American Journal of Clinical Dermatology 1(4): 225-234, 2000

Cutaneous toxicity by ftorafur, hand-foot or palmar-plantar erythrodysesthesia syndrome. Revista Clinica Espanola 188(3): 165-166, 1991

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Annals of Oncology 18(7): 1159-1164, 2007

Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. American Journal of Clinical Dermatology 1(4): 225-234, 2001

Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease. Archives of Dermatology 144(8): 1081-1082, 2008

Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 111(8): 688-689, 1989

Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 101(6): 798-799, 1984

Fluorouracil and the palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 102(3): 419, 1985

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20(10): 1221-1223, 2000

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. Annals of Oncology 16(7): 1210-1211, 2005

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies. Supportive Cancer Therapy 1(4): 213-218, 2008

Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori 74(3): 329-331, 1988

Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. Journal of the European Academy of Dermatology and Venereology 31(6): E304-E306, 2016

Palmar-plantar erythrodysesthesia. BMJ Case Reports 2015, 2016